유한양행

000100KOSPI

55.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 6.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Yuhan is a company engaged in the manufacturing and sales of pharmaceuticals, chemicals, and daily necessities, with key products such as Lexapro, Antipurin, and DuoWell. In 2024, the company achieved a 5.7% revenue growth to 21.87 trillion won, despite challenges like geopolitical tensions and economic downturns. R&D efforts are highlighted by Lexapro's global commercialization and ongoing pipeline development, while operating profit and net income increased by 90.2% and 235.9% year-over-year, respectively.

Number of Employees

2,153people

Average Salary

100.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

32.97Industry Average 15.000.0Point

2.2x industry avg (risky)

PBR

2.59Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

8.21Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

5.30Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲43.4% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 5.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 83,000Won52-week high 125,00052-week low 66,400

1-month return4.0Point

1m +6.68% (slight rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02